Hemlibra is a bispecific factor IXa- and factor X-directed antibody. It is designed to bring together factor IXa and factor X, proteins required to activate the natural coagulation cascade and restore the blood clotting process for people with haemophilia A. Hemlibra is a prophylactic (preventative) treatment that can be administered by an injection of a ready-to-use solution under the skin (subcutaneously) once-weekly, every two weeks or every four weeks (after an initial once weekly dose for the first four weeks). Hemlibra was created by Chugai Pharmaceutical Co., Ltd. and is being co-developed globally by Chugai, Roche and Genentech. It is marketed in the United States by Genentech as Hemlibra (emicizumab-kxwh), with kxwh as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the US Food and Drug Administration.
Global Hemlibra sales increased from CHF 226 Million in 2018 to CHF 1,380 Million in 2019. In the United States, sales grew due to broader market penetration....Please Visist the Link for forecasted revenue: http://www.mngtracker.com/drug/hemlibra
MNG Tracker is a market research company which offer market research reports and database subscription service. No Need to Pay, No Need to SignUp - Just Click and Access the Company Drugs Details. You can access drugs details by company name, by therapeutic area or by drugs name. Each drug details includes drugs revenue globally, regionally and country specific. We also provides the historical and estimated drug revenue along with supportive driving factors.
Drugs Store: This segment is arranged in three ways. Please click on link to access the information for
By Company Drugs: http://www.mngtracker.com/company-drugs-detail
Thanks and Best Regards